【科技自立·产业自强】亚辉龙：承担多项国家及省市重大科技项目 产品覆盖自身免疫、心血管等七大领域

Core Insights - The company has established six major R&D centers and a production base in Xiangtan, Hunan, undertaking several significant national and provincial scientific projects [1] - The "High-Performance Immuno Rapid Detection System R&D" project is included in the "14th Five-Year" National Key R&D Program, addressing clinical issues such as complex interference in whole blood sample testing, low sensitivity, and long detection times [1] - Since the project's inception, the company has applied for 18 invention patents and has obtained a registration certificate for myocardial marker composite quality control products [1] - As of August 31, 2025, the company plans to apply for a total of 760 patents, with 59% being invention patents [1] - The company emphasizes industry-academia-research collaboration, establishing joint laboratories with prestigious institutions like Peking University and the Chinese Academy of Sciences to foster high-level professional talent and advance technology in the in vitro diagnostics field [1]